Prostate cancer is a malignant tumor, which arises in the prostate gland of the male reproductive system located below the urinary bladder and in front of the rectum. It occurs in men over the age of 50 and may become life threatening.Treatment options for prostate cancer include observation, radiation therapy, surgery, hormone therapy, and chemotherapy. The global prostate cancer therapeutics market will reach 15.26 billion USD by 2025 from 9.12 billion USD in 2018 with a CAGR of 7.63% during the forecast period.
Growth by Region
North America will be the leading contributor to the market during the forecast period due to increasing prostate cancer patients and high investments in R&D. Asia Pacific and Latin America are predicted to display significant growth in the market due to rising awareness about the disease.
Drivers vs Constraints
The rising incidences of prostate cancer is fueling the market growth. Adoption of various technologies in diagnostics test is as key factor for the growth of the market. On the other hand, high cost of treatment is hindering the growth of the market.
Industry Trends and Updates
Clinical Laserthermia Systems and Exact Imaging are joining forces to market image-guided laser surgery to treat prostate cancer and benign prostatic hyperplasia
MDxHealth announced that it has signed a worldwide licensing agreement with Philips for the rights to manufacture and market Philips' recently validated phosphodiesterase-4D7 prostate cancer biomarker as a prognostic test.
Global Prostate Cancer Therapeutics Market – by Therapy, Drugs, Distribution, Region - Market Size, Demand Forecasts, Company Profiles, Industry Trends and Updates (2018 - 2025)
1. Research Methodology
2. Executive Summary
3. Market Overview
3.1. Definition
3.2. Industry Value Chain Analysis
3.3. Porter's 5 Forces
3.4. Regulations
4. Market Dynamics
4.1. Introduction
4.2. Drivers
4.3. Constraints
4.4. Trends
5. Global Prostate Cancer Therapeutics Market Segmentation, Forecasts and Trends - by Therapy
5.1. Hormone Therapy
5.2. Chemotherapy
5.3. Biologic Therapy
5.4. Targeted Therapy
5.5. Others
6. Global Prostate Cancer Therapeutics Market Segmentation, Forecasts and Trends - by Drugs
6.1. Zytiga
6.2. Gonax
6.3. Taxotere
6.4. Jevtana
6.5. Provenge
6.6. Zoladex
6.7. Others
7. Global Prostate Cancer Therapeutics Market Segmentation, Forecasts and Trends - by Distribution
7.1. Hospital Pharmacy
7.2. Retail Pharmacy
7.3. Online Sales
7.4. Others
8. Global Prostate Cancer Therapeutics Market Segmentation, Forecasts and Trends - by Region
8.1. North America
8.1.1. U.S.
8.1.2. Canada
8.1.3. Mexico
8.2. Europe
8.2.1. UK
8.2.2. France
8.2.3. Germany
8.2.4. Italy
8.2.5. Others
8.3. Asia Pacific
8.3.1. India
8.3.2. China
8.3.3. Japan
8.3.4. Australia
8.3.5. Others
8.4. South America
8.4.1. Brazil
8.4.2. Argentina
8.4.3. Others
8.5. Middle East and Africa
8.5.1. South Africa
8.5.2. UAE
8.5.3. Saudi Arabia
8.5.4. Egypt
8.5.5. Others
9. Competitive Intelligence
9.1. Company Market Share Analysis
9.2. Industry M&As, Consolidations
10. Company Profiles
10.1. AstraZeneca
10.2. Sanofi-Aventis
10.3. Ipsen
10.4. Tolmar
10.5. Abbott
10.6. Astellas Pharma
10.7. Indevus
10.8. Dendreon
10.9. Ferring
10.10. Bristol-Myers Squibb
10.11. Pfizer
10.12. Sanofi
10.13. Teva
10.14. Takeda
10.15. Johnson & Johnson
10.16. Others
11. Investment Opportunities